Prevention of MKK6-dependent activation by binding to p38α MAP kinase

Biochemistry

Volumn 44, Issue 50, 2005, Pages 16475-16490

  Sullivan, Jane E ^a   Holdgate, Geoffrey A ^a   Campbell, Douglas ^a   Timms, David ^a   Gerhardt, Stefan ^a   Breed, Jason ^a   Breeze, Alexander L ^a   Bermingham, Alun ^a   Pauptit, Richard A ^a   Norman, Richard A ^a   Embrey, Kevin J ^a   Read, Jon ^a   VanScyoc, Wendy S ^a   Ward, Walter H J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINETRIPHOSPHATE; CATALYST ACTIVITY; CATALYST SELECTIVITY; CONFORMATIONS; CRYSTAL STRUCTURE; ENZYME INHIBITION; ENZYMES;

ACTIVATION LOOP; INFLAMMATORY DISORDERS; MAP KINASE;

ACTIVATION ANALYSIS;

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE TRIPHOSPHATE; AMINE; ASPARTIC ACID; CYTOKINE; DORAMAPIMOD; GLYCINE; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PHENYLALANINE; PURINE; QUINAZOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; RO 3201195; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CATALYSIS; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MAP KINASE KINASE 6; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS;

EID: 29244448317     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi051714v     Document Type: Article

References (59)

1. Lee, J. C., Kassis, S., Kumar, S., Badger, A., and Adams, J. L. (1999) p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials, Pharmacol. Ther. 82, 389-397.
2. Kumar, S., Boehm, J., and Lee, J. C. (2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases, Nat. Rev. Drug Discov. 2, 717-726.
3. Pargellis, C., and Regan, J. (2003) Inhibitors of p38-mitogen-activated protein kinase for the treatment of rheumatoid arthritis, Curr. Opin. Invest. Drugs 4, 566-571.
4. Young, P. R., McLaughlin, M. M., Kumar, S., Kassis, S., Doyle, M. L., McNulty, D., Gallagher, T. F., Fisher, S., McDonnell, P. C., Carr, S. A., Huddleston, M. J., Seibel, G., Porter, T. G., Livi, G. P., Adams, J. L., and Lee, J. C. (1997) Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site, J. Biol. Chem. 272, 12116-12121.
5. Frantz, B., Klatt, T., Pang, M., Parsons, J., Rolando, A., Williams, H., Tocci, M. J., O'Keefe, S. J., and O'Neill, E. A. (1998) The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding, Biochemistry 37, 13846-13853.
6. Raingeaud, J., Whitmarsh, A. J., Barrett, T., Derijaard, B., and Davis, R. J. (1996) MKK3- and MKK6-gene regulated expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway, Mol. Cell. Biol. 16, 1247-1255.
7. Brancho, D., Tanak, M., Jaeschke, A., Ventura, J. J., Kelkar, N., Tanaka, Y., Kyuuma, M., Takeshita, T., Flavell, R. A., and Davis, R. J. (2003) Mechanism of p38 MAP kinase activation in vivo, Genes Dev. 17, 1969-1978.
8. Ge, B., Gram, H., Padova, F., Huang, B., New, L., Ulvetich, R. J., Luo, Y., and Man, J. (2002) MAPKK-independent activation of p38α mediated by TAB1-dependent autophosphorylation of p38α, Science 295, 1291-1294.
9. Wang, Z., Harkins, P. C., Ulevitch, R. J., Han, J., Cobb, M. H., and Goldsmith, E. J. (1997) The structure of mitogen-activated protein kinase p38 at 2.1 Å resolution, Proc. Natl. Acad. Sci. U.S.A. 94, 2327-2332.
10. Bellon, S., Fitzgibbon, M. J., Fox, T., Hsiao, H.-M., and Wilson, K. P. (1999) The structure of phosphorylated p38γ is monomeric and reveals a conserved activation-loop conformation, Structure 7, 1057-1065.
11. Johnson, L. N., Noble, M. E. M., and Owen, D. J. (1996) Active and inactive protein kinases: Structural basis for regulation, Cell 85, 149-158.
12. Chang, C.-I., Xu, B.-e., Akella, R., Cobb, M. H., and Goldsmith, E. J. (2002) Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b, Mol. Cell 9, 1241-1249.
13. Adams, J. A. (2003) Activation loop phosphorylation and catalysis in protein kinases. Is there functional evidence for the autoinhibitor model?, Biochemistry 42, 601-607.
14. Cherry, M., and Williams, D. H. (2004) Recent kinase and kinase inhibitor X-ray structures: Mechanisms of inhibition and selectivity insights, Curr. Med. Chem. 11, 663-673.
15. Cohen, P. (2002) Protein kinases - the major drug targets of the twenty-first century?, Nat. Rev. Drug Discov. 1, 309-315.
16. Lisnock, J. M., Tebben, A., Frantz, B., O'Neill, E. A., Croft, G., O'Keefe, S. J., Li, B., Hacker, C., de Laszlo, S., Smith, A., Libby, B., Liverton, N., Hermes, J., and LoGrasso, P. (1998) Molecular basis for p38 protein kinase inhibitor specificity, Biochemistry 37, 16573-16581.
17. Gumming, J. G., McKenzie, C. L., Bowden, S. G., Campbell, D., Masters, D. J., Breed, J., and Jewsbury, P. J. (2004) Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase, Bioorg. Med. Chem. Lett. 14, 5389-5394.
18. Dumas, J., Hatoum-Mokdad, H., Sibley, R., Riedl, B., Scott, W. J., Monahan, M. K., Lowinger, T. B., Brennan, C., Natero, R., Turner, T., Johnson, J. S., Schoenleber, R., Bhargava, A., Wilhelm, S. M., Housely, T. J., Ranges, G. E., and Shrikhande, A. (2000) 1-phenyl-5-pyrazolyl ureas: Potent and selective p38 kinase inhibitors, Bioorg. Med. Chem. Lett. 10, 2051-2054.
19. Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., and Regan, J. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric site, Nat. Struct. Biol. 9, 268-272.
20. Regan, J., Pargellis, C. A., Cirillo, P. F., Gilmore, T., Hickey, E. R., Peet, G. W., Proto, A., Swinamer, A., and Moss, N. (2003) The kinetics of binding to p38 MAP kinase by analogues of BIRB 796, Bioorg. Med. Chem. Lett. 13, 3101-3104.
21. Kuma, Y., Sabio, G., Bain, J., Shapiro, N., Márquez, R., and Cuenda, A. (2005) BIRB0796 inhibits all p38 MAPK isoforms in vitro and in vivo, J. Biol. Chem. 280, 19472-19479.
22. Shewchuk, L., Hassell, A., Wisely, B., Rocque, W., Holmes, W., Veal, J., and Kyper, L. F. (2000) Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4- anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase, J. Med. Chem. 43, 133-138.
23. Gallagher, T. F., Seibel, G. L., Kassis, S., Laydon, J. T., Blumenthal, M. J., Lee, J. C., Lee, D., Boehm, J. C., Fier-Thompson, S. M., Abt, J. W., Soreson, M. E., Smietana, J. M., Hall, R. F., Garigipati, R. S., Bender, P. E., Erhard, K. F., Krog, A. J., Hoffmann, G. A., Sheldrake, P. L., McDonnell, P. C., Kumar, S., Young, P. R., and Adams, J. L. (1997) Regulation of stress-induced cytokine production by pyridinylimidazoles; Inhibition of CSBP kinase, Bioorg. Med. Chem. 5, 49-64.
24. Crawley, G. C., McKerrecher, D., Poyser, J. P., Hennequin, L. F., Ple, P., and Lambert, C. M.-P. (2001) Quinazoline derivatives, International Patent WO 01/04102.
25. Labadie, S. S., Rotstein, D. M., Sjogren, E. B., and Talamas, F. X. (1999) Preparation of 5-aminopyrazole derivatives as p38 MAP kinase inhibitors, International Patent WO 99/57101.
26. Leslie, A. G. W. (1992) Recent changes to the MOSFLM package for processing film and image plate data, Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography, No. 26.
27. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. D50, 760-763.
28. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of Macromolecular structures by the maximum-likelihood method, Acta Crystallogr. D53, 240-255.
29. Tugarinov, V., Muhandiram, R., Ayed, A., and Kay, L. E. (2002) Four-dimensional NMR spectroscopy of a 723-residue protein: Chemical shift assignments and secondary structure of malate synthase G, J. Am. Chem. Soc. 124, 10025-10035.
30. Loria, J. P., Ranee, M., and Palmer, A. G., III (1999) Transverse-relaxation-optimized (TROSY) gradient-enhanced triple-resonance NMR spectroscopy, J. Magn. Reson. 141, 180-184.
31. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) NMRPipe: A multidimensional spectral processing system based on UNIX pipes, J. Biomol. NMR 6, 277-293.
32. Johnson, B. A., and Blevins, R. A. (1994) NMRView: A computer program for the visualization and analysis of NMR data, J. Biomol. NMR 4, 603-614.
33. Karlsson, R. (1994) Real-time competitive analysis of interactions between low-molecular-weight ligands in solution and surface-immobilized receptors, Anal. Biochem. 221, 142-151.
34. Leatherbarrow, R. J. (1996) GraFit (Version 3.09b), Erithacus Software, Staines, U.K.
35. Mannervik, B. (1982) Regression analysis, experimental error, and statistical criteria in the design and analysis of experiments for discrimination between rival kinetic models, Methods Enzymol. 87, 370-390.
36. Christopoulos, A. (1998) Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log, Trends Pharmacol. Sci. 19, 351-357.
37. 50) of an enzymatic reaction, Biochem. Pharmacol. 22, 3099-3108.
38. Morrison, J. F., and Walsh, C. T. (1988) The behaviour and significance of slow-binding enzyme inhibitors, Adv. Enzymol. 61, 201-301.
39. Fersht, A. R. (1998) Structure and mechanism in protein science, W. H. Freeman, New York.
40. LoGrasso, P. V., Frantz, B., Rolando, A. M., O'Keefe, S. J., Hermes, J. D., and O'Neill, E. A. (1997) Kinetic mechanism for p38 MAP kinase, Biochemistry 36, 10422-10427.
41. Chen, G., Porter, M. D., Bristol, J. R., Fitzgibbon, M. J., and Pazhanisamy, S. (2000) Kinetic mechanism of the p38α MAP kinase: Phosphoryl transfer to synthetic peptides, Biochemistry 39, 2079-2087.
42. Wang, Z., Canagarajah, B. J., Boehm, S. C., Kassisà, S., Cobb, M. H., Young, P. R., Abdel-Meguid, S., Adams, S. L., and Goldsmith, E. J. (1998) Structural basis of inhibitor selectivity in MAP kinases, Structure 6, 1117-1128.
43. Kumar, S., Jiang, M. S., Adams, J. L., and Lee, J. C. (1999) Pyridinylimidazole compound SB203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase, Biochem. Biophys. Res. Commun. 263, 825-831.
44. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase, Science 289, 1938-1942.
45. Wan, P. T. C., Bargett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., and Marais, R. (2004) Mechanism of activation of the RAF-ERK singaling pathway by oncogenic mutations of B-RAF, Cell 116, 855-867.
46. Manley, P. W., Bold, G., Brüggen, J., Fendrich, G., Furet, P., Mestan, J., Schnell, C., Stolz, B., Meyer, T., Meyhack, B., Stark, W., Strauss, A., and Wood, J. (2004) Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis, Biochim. Biophys. Acta 1697, 17-27.
47. Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., Alligood, K. J., Rusnak, D. W., Gilmer, T. M., and Shewchuk, L. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): Relationship among protein conformation, inhibitor off-rate, and receptor activity in tumour cells, Cancer Res. 64, 6652-6659.
48. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. (1995) PD 098059 is a specific inhibitor of mitogen-activated protein kinase kinase in vitro and in vivo, J. Biol. Chem. 270, 27489-27494.
49. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors, Biochem. J. 351, 95-105.
50. Ohren, J. F., Chen, H., Pavlovsky, A., Whitehead, C., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C., Mueller, W. T., Delaney, A., Omer, C., Sebolt-Leopold, J., Dudley, D. T., Leung, I. K., Flamme, C., Warmus, J., Kaufman, M., Barrett, S., Tecle, H., and Hasemann, C. A. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition, Nat. Struct. Mol. Biol. 11, 1192-1197.
51. Greenbaum, A. L., Gumaa, K. A., and McLean, P. (1971) The distribution of hepatic metabolites and the control of pathways of carbohydrate metabolism in animals of different dietary and hormonal status, Arch. Biochem. Biophys. 143, 617-663.
52. Knight, Z. A., and Shokat, K. M. (2005) Features of selective kinase inhibitors, Chem. Biol. 12, 621-637.
53. Branger, J., van den Blink, B., Weijer, S., Madwed, J., Bos, C. L., Gupta, A., Yong, C.-L., Polmar, S. H., Olszyna, D. P., Hack, C. E., van Deventer, S. J. H., Peppelenbosch, M. P., and van der Poll, T. (2002) Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during endotoxemia, J. Immunol. 168, 4070-4077.
54. Hubbard, S. R., and Till, J. H. (2000) Protein tyrosine kinase structure and function, Annu. Rev. Biochem. 69, 373-398.
55. Huse, M., and Kuriyan, J. (2002) The conformational plasticity of protein kinases, Cell 109, 275-282.
56. Cleland, W. W. (1963) The kinetics of enzyme-catalyzed reactions with two or more substrates or products. II. Inhibition: nomenclature and theory, Biochim. Biophys. Acta 67, 173-187.
57. Segel, I. H. (1975) in Enzyme Kinetics, pp 203-208. Wiley, New York.
58. Morrison, J. F., and Cleland, W. W. (1980) A kinetic method for determining dissociation constants for metal complexes of adenosine 5′-triphosphate and adenosine 5′-disphosphate. Biochemistry 19, 3127-3131.
59. Morrison, J. F., and Cleland, W. W. (1983) Lanthanide-adenosine 5′-triphosphate complexes: Determination of their dissociation constants and mechanism of action as inhibitors of yeast hexokinase, Biochemistry 22, 5507-5513.